Long-term Drug Persistence and Clinical Outcomes of Ustekinumab in Crohn's Disease: A Multicenter Real-World Study from the Hokkaido Phoenix Cohort
Clicks: 1
ID: 318006
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #33 of 38 articles by views in Crohn s & Colitis 360
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Although ustekinumab (UST) is effective in Crohn’s disease (CD), long-term real-world data beyond 5 years and its effects on extraintestinal manifestations remain limited. We evaluated UST’s long-term effectiveness and safety in CD. Methods This multicenter retrospective study enrolled 317 CD patients who initiated UST between May 2017 and February 2023 at seven institutions in Japan. The primary outcome was the UST continuation rate. The secondary outcomes included factors affecting the continuation rates, surgery-free survival, endoscopic remission rates, improvement in perianal and extraintestinal manifestations, and adverse events. Results UST continuation rates at 1, 3, and 5 years were 87.6%, 69.6%, and 66.8%, respectively, with 43 patients followed beyond 5 years (maximum 6.1 years). Multivariate analysis identified week-8 albumin ≥3.3 g/dL (HR 0.30; 95%CI 0.12–0.72; p = 0.007) and week-8 C-reactive protein (CRP) ≥0.33 mg/dL (HR 2.05; 95%CI 1.14–3.69; p = 0.016) as independent predictors of continuation. Endoscopic remission rates improved significantly from baseline (10%) to week 52 (19%, p < 0.01) and week 104 (30%, p < 0.01). Among perianal fistula cases (n = 60), 28% achieved clinical fistula remission and 37% showed improvement. Resolution or improvement was observed in 76% of arthritis and 86% of psoriasis-like lesion cases. The surgery-free survival rate at 5 years was 85.1%. The adverse event rate was 10.7%. Conclusions UST demonstrated favorable medium- to long-term effectiveness and safety in CD patients with limited follow-up data beyond 5 years. Week-8 albumin and CRP levels may serve as early predictive biomarkers but require external validation in independent cohorts.
| Reference Key |
openalex_W7165405320
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Takahiro Ito, Atsuo Maemoto, Nobuhiro Ueno, Mikihiro Fujiya, Toshifumi Ashida, Daisuke Hirayama, Yoshihiro Yokoyama, Satoshi Motoya, Masanao Nasuno, Hiroki Tanaka, Takehiko Katsurada, Hiroshi Nakase |
| Journal | Crohn s & Colitis 360 |
| Year | 2026 |
| DOI |
10.1093/crocol/otag059
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.